Search results
Results from the WOW.Com Content Network
A phase III study of sunitinib treatment in well differentiated pNET that had worsened within the past 12 months (either advanced or metastatic disease) showed that sunitinib treatment improved progression-free survival (11.4 months vs. 5.5 months), overall survival, and the objective response rate (9.3% vs. 0.0%) when compared with placebo.
Although estimates vary, the annual incidence of clinically significant neuroendocrine tumors is approximately 2.5–5 per 100,000; [103] two thirds are carcinoid tumors and one third are other NETs. The prevalence has been estimated as 35 per 100,000, [ 103 ] and may be considerably higher if clinically silent tumors are included.
Although it accounts for only 2.5% of new cases, pancreatic cancer is responsible for 6% of cancer deaths each year. [118] It is the seventh-highest cause of death from cancer worldwide. [10] Pancreatic cancer is the fifth most-common cause of death from cancer in the United Kingdom, [19] and the third most-common in the United States. [20]
Five-year relative survival rates describe the percentage of patients with a disease alive five years after the disease is diagnosed, divided by the percentage of the general population of corresponding sex and age alive after five years. Typically, cancer five-year relative survival rates are well below 100%, reflecting excess mortality among ...
66% of responders reported a VAS pain score of 0 or 1 with a greater than 7-point reduction in pain score at 4-6 weeks post-procedure. 100% of our responder group had clinically meaningful pain relief at 4-6 weeks post-procedure. Pain relief was experienced as quick as 1-day post-procedure for the three patients in the responder group.
Insulinomas are rare neuroendocrine tumours with an incidence estimated at one to four new cases per million persons per year. Insulinoma is one of the most common types of tumours arising from the islets of Langerhans cells (pancreatic endocrine tumours). Estimates of malignancy (metastases) range from 5 to 30%.
Small cell lung cancer has a five-year survival rate of 4% according to Cancer Centers of America's Website. [5] The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year ...
The major clinical features are prolonged watery diarrhea (fasting stool volume > 750 to 1000 mL/day) and symptoms of hypokalemia and dehydration. Half of the patients have relatively constant diarrhea while the rest have alternating periods of severe and moderate diarrhea. One third have diarrhea < 1yr before diagnosis, but in 25%, diarrhea is ...